Somer Abdelfattah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Somer Abdelfattah has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Akshada Sawant
Rutgers Cancer Institute, Rutgers University
30 shared publications - Chang S. Chan
Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA
30 shared publications - Christian S. Hinrichs
Rutgers Cancer Institute, New Brunswick, NJ, USA
30 shared publications - Edmund C. Lattime
Rutgers Cancer Institute of New Jersey, New Brunswick, USA
30 shared publications - Eduardo Cararo Lopes
Rutgers Cancer Institute, Rutgers University
30 shared publications - Eileen White
Rutgers Cancer Institute, Rutgers University, New Brunswick, USA
30 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Figures with Legends.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Figures with Legends.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 2A presents recurrently mutated genes in Pold1 D400A mutant tumor samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 2A presents recurrently mutated genes in Pold1 D400A mutant tumor samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
The figure presents the tumor incidence and mean survival plots for the Pold1 D400A and Pole L424V mice treated with immunotherapy before observable tumors appeared.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
The figure presents the tumor incidence and mean survival plots for the Pold1 D400A and Pole L424V mice treated with immunotherapy before observable tumors appeared.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 1A presents mutations exclusive to Pold1 D400A_10G mice compared to ancestral Pold1 D400A mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 1A presents mutations exclusive to Pold1 D400A_10G mice compared to ancestral Pold1 D400A mice.